India, April 13 -- Revolution Medicines (RVMD), a late-stage oncology company, saw its shares surge by more than 35% after the firm announced positive topline results from the Phase 3 RASolute 302 clinical trial evaluating Daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. The trial met all primary and key secondary endpoints.
Following the news, RVMD is up 35.55%, up $130.71.
Company Profile
Revolution Medicines develops therapies for RAS-addicted cancers.
The firm's lead devlopment RAS(ON) inhibitors include Daraxonrasib (RMC-6236), Elironrasib G12C (RMC-6291) and Xoldonrasib G12D (RMC-9805).
Daraxonrasib is an investigational, oral RAS(ON) multi-selective, non-covalent i...